Recombinant human albumin

Novozymes has developed a range of recombinant human albumins (rHAs) (LONG R³IGF-I, Albufuse, CellPrime rAlbumin AF-S) suitable for industrial cell culture and biomedical applications, such as protein, drug and vaccine formulation and medical device coating.

The microbially expressed rHAs offer the benefits of albumin in a compliant, consistent way and are a suitable replacement to animal- and human-derived sources.

LONG R³IGF-I is a recombinant analogue of IGF-I and an alternative to recombinant insulin, which has been used in the manufacture of several USFDA EMEA and Japanese FDA-approved biopharmaceuticals. It is available in both a powder and a liquid formulation, which can be diluted directly into culture media for greater ease of use.

Developed as an iron supplement for cell culture, CellPrime rTransferrin is an animal-free, recombinant replacement for human- and animal-derived transferrin and chemical-based chelators. Expressed in Novozymes’ S. cerevisiae system as the holo form, CellPrime rTransferrin binds specifically to the transferrin receptor, providing efficient iron uptake into the cell for increased cell culture performance.

Albufuse albumin fusion technology represents a simple, flexible platform designed to produce proteins with extended circulatory half-life. It enables the genetic fusion of a client’s target protein to albumin at the molecular level and avoids the extra costs associated with alternative chemical-based methods.